Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 5 mg | $30.00 | In stock | — |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
Thymosin alpha-1 (thymalfasin) is a peptide of 28 amino acids, acetylated at the N-terminus, first isolated from a thymus extract called thymosin fraction 5.
Identity
| Type | Synthetic peptide, 28 amino acids, N-terminal acetylated |
|---|---|
| Molecular formula | C129H215N33O55 |
| Molecular weight | 3108.3 g/mol |
| CAS number | 62304-98-7 |
| PubChem CID | 16130571 |
Thymosin alpha-1 is a linear peptide of 28 amino acids, Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH, acetylated at the N-terminal serine and with a free C-terminal acid. Molecular formula C129H215N33O55, molecular weight 3108.3 g/mol (PubChem CID 16130571, CAS 62304-98-7). It contains no cysteine, methionine or aromatic residue, and with nine glutamic and aspartic acid residues against four lysines it is strongly acidic. Mass spectrometry confirms the full-length acetylated peptide and distinguishes it from deletion or deacetylated forms, which HPLC also separates when it reports purity. It is supplied as a lyophilized powder in a sealed vial.
What the published research covers
It has been studied for its effects on T cells and other immune cells, in the laboratory and in clinical trials in several countries.
Thymosin alpha-1 was isolated from thymosin fraction 5, a calf thymus extract studied in the laboratory of Allan Goldstein. In 1977 the group reported its sequence: a heat-stable, highly acidic polypeptide of 28 residues, one of several in the fraction thought to take part in the regulation, differentiation and function of T cells (Goldstein, 1977). The peptide used in later research and clinical work is made synthetically and is also called thymalfasin.
Laboratory work has focused on innate and adaptive immune cells. In dendritic cells exposed to the fungus Aspergillus fumigatus, the peptide induced functional maturation and interleukin-12 production through MyD88-dependent Toll-like receptor signaling; in mice that had received hematopoietic transplants, it activated Th1-dependent antifungal immunity, accelerated recovery of myeloid cells and protected the animals from aspergillosis (Romani, 2004). Clinical research has been carried out mainly in Asia and Europe. A Cochrane review of thymosin alpha-1 in chronic hepatitis B included 10 randomized trials with 1,349 participants, published between 1991 and 2018 in Bangladesh, China, Italy, Korea, Singapore and Taiwan, and rated the certainty of the evidence as very low for every outcome except serious adverse events, which it rated low (Naing, 2026). A multicenter phase 3 trial, TESTS, randomized 1,106 adults with sepsis at 22 centers in China; 28-day all-cause mortality was 23.4% in the thymosin alpha-1 group and 24.1% in the placebo group, a difference that was not significant, and no secondary or safety outcome differed between the groups. Prespecified subgroup analyses suggested possible differences by age and by diabetes (Wu, 2025).
Much of the clinical literature consists of small or open-label trials, and the Cochrane reviewers judged the hepatitis B trials to carry a high risk of bias or some concerns about it, with imprecise estimates. Where a large placebo-controlled trial has been run, in sepsis, it did not show a difference in mortality, and subgroup findings of that kind need their own trials before they can be relied on. The mechanistic findings come largely from cell culture and mouse models.
Regulatory status
Approved as a prescription product in a number of countries outside the United States. Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is thymosin alpha-1 offered in?
- Vials of 5 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this the approved medicine?
- No. Thymalfasin is approved as a prescription product, under the name Zadaxin, in a number of countries outside the United States. This material is a research peptide of the same sequence, supplied for laboratory research only and not approved by the FDA for any use.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Goldstein AL et al. (1977). Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. Proceedings of the National Academy of Sciences of the United States of America. PubMed 265536
- Romani L et al. (2004). Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. PubMed 14982877
- Wu J et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ (Clinical Research Edition). PubMed 39814420
- Naing C et al. (2026). Thymosin-ɑ1 for people with chronic hepatitis B. The Cochrane Database of Systematic Reviews. PubMed 42713852
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement